Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/18/2024 | $22.00 → $31.00 | Neutral → Buy | BofA Securities |
8/15/2024 | $33.00 | Overweight | Piper Sandler |
12/15/2023 | $25.00 → $15.00 | Buy → Neutral | BofA Securities |
6/30/2023 | $27.00 | Outperform | Wedbush |
2/3/2023 | $17.00 | Outperform | Oppenheimer |
6/23/2022 | $12.00 | Buy | H.C. Wainwright |
3/8/2022 | $31.00 → $27.00 | Hold → Buy | Jefferies |
11/8/2021 | $19.00 → $31.00 | Buy → Hold | Jefferies |
4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
CARLSBAD, Calif., Nov. 13, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Jefferies London Healthcare Conference, November 19-21st, 2024: Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, November 19th, at 2:00 pm GMT.TYRA management will also participate in one-on-one investor meetings and B2B meetings.36th Annual Piper Healthcare Conference, December 3-5th, 2024, New York: Mr. Har
- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30
– TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies – – First child with achondroplasia expected to be dosed in Q1 2025 – CARLSBAD, Calif., Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 for children with achondroplasia (BEACH301). TYRA-300 is a
BofA Securities upgraded Tyra Biosciences from Neutral to Buy and set a new price target of $31.00 from $22.00 previously
Piper Sandler initiated coverage of Tyra Biosciences with a rating of Overweight and set a new price target of $33.00
BofA Securities downgraded Tyra Biosciences from Buy to Neutral and set a new price target of $15.00 from $25.00 previously
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday. Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-than-expected quarterly financial results. The finance behemoth reported second-quarter adjusted earnings per share of $1.51, beating the street view of $1.43. Quarterly revenue of $4.597 billion, an increase of 2% year-over-year, surpassed the analyst consensus of $4.523 billion, according to data from Benzinga Pro. Bank of New York Mellon shares surged 4.3% to $64.12 on Friday. Here are some other big stocks recording gains in today’s session. Lucid Group, Inc. (NASDAQ:LCID) sh
Oppenheimer analyst Matthew Biegler reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and maintains $28 price target.
Wedbush analyst Robert Driscoll reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and maintains $28 price target.
- Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif., Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, ann
CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain. Gary Ste
- In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024--Conference call and webcast today, March 1st, at 8:00 am ET- CARLSBAD, Calif., March 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Ima
10-Q - Tyra Biosciences, Inc. (0001863127) (Filer)
8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
144 - Tyra Biosciences, Inc. (0001863127) (Subject)
SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)
SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30
-Dr. Warner brings over twenty years of proven clinical development leadership to TYRA having successfully led global development and secured approvals for medicines across oncology and skeletal disease- CARLSBAD, Calif., Sept. 10, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Doug Warner, M.D., as Chief Medical Officer. Dr. Warner will be responsible for overseeing TYRA's clinical portfolio and will serve as a key member of its executive management team. "TYRA is a
CARLSBAD, Calif., May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced changes to its Board of Directors with the appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D. The changes are effective immediately. "Susan and Michael's impressive careers will provide TYRA with valuable guidance as we advance our potential next-generation precision candidates toward people in need. We have a unique op